Starpharma shares soar on back of AstraZeneca collaboration; Jim Allison wins Lasker award;

@FierceBiotech: Purdue puts up $213M for a novel pain drug from VM Pharma. Report | Follow @FierceBiotech

@JohnCFierce: AstraZeneca nabs priority review voucher as Wellstat bags FDA OK. Report | Follow @JohnCFierce

@DamianFierce: NYT editorial takes a weird, non-systemic middle ground on PCSK9 pricing. Article | Follow @DamianFierce

> Shares of Melbourne, Australia-based Starpharma (ASX: SPL, OTCQX: SPHRY) soared today after the company announced a collaboration with AstraZeneca ($AZN), putting their drug delivery tech to work for the pharma giant. Starpharma grabbed a $2 million upfront with milestones ranging up to $124 million for the first product, with more to come if it extends to additional programs. Release

> Jim Allison, an immuno-oncology expert now at MD Anderson, won the prestigious Lasker-DeBakey Clinical Medical Research Award. Report

> Tampa, FL-based Oxis Biotech inked a license agreement to further develop and commercialize DT2219ARL, a novel therapy for B cell cancers, leukemias and lymphomas. Release

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Focus Diagnostics gets FDA blessing to expand label for herpes test. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI Friday: Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Article | Follow @StacyALawrence

@EmilyWFierce: ICYMI from FiercePharma: Novartis snags EU approval for multiple myeloma med Farydak. Report | Follow @EmilyWFierce

> GSK-backed SetPoint raises $15M to advance anti-inflammatory, neuromodulation device. Article

> Novartis CEO: Smart contact lenses 'progressing well' with first human trials set for 2016. Report

Pharma News

@FiercePharma: Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. More from FiercePharmaAsia  | Follow @FiercePharma

@CarlyHFierce: ICYMI Friday: AstraZeneca scores FDA nod for long-term Brilinta use. Article | Follow @CarlyHFierce

> Perrigo's fate is in shareholders' hands, Mylan chairman says. Or is it? Story

> Roche CEO lashes out at U.K.'s 'stupid' move to stop paying for a dozen-plus cancer meds. More

> Study: Pfizer's Chantix does not increase risk of depression, heart attack in smokers. Report

Animal Health News

> Report: Bees self-medicate to protect against parasites. More

> Nexvet doubles down on R&D spending as net loss widens. Report

> Veterinarian's op-ed piece says antibiotic ban taking tools away from vets. Article

> New mobile app allows virtual veterinary consultations. Item

> UC Davis veterinarian pushes 'One Health' system for scientific literature. Story

Biotech IT News

> NIH commits $49M to fuel fusion of genomic data and EHRs. News

> Labfolder taps investors for cash to develop ELN system. Report

> Thermo Fisher rolls out Ion S5 sequencer in play for clinical trial sector. Story

> CD Genomics adds HiSeq X Ten to suite of tools for sequencing services. Item

> Google hooks up with Sanofi to continue diabetes drive. Article

Drug Delivery News

> Gene therapy approach for T1 diabetes could alter immune system to boost insulin. Report

> Sanofi looking to expand U.K. plant that does contract manufacturing of inhaled meds. Story

> Columbia U. team delivers small liquid drug doses to the lungs for targeted treatment. More

> Study finds e-cigarettes are being used to vaporize pot. Item

> Generic alternative to Novartis' transdermal patch for Alzheimer's hits the market. Article

Pharma Manufacturing News

> Recipharm to buy Alcon plant as part of manufacturing agreement. News

> GSK runs into supply issues after China plant damaged by nearby explosion. More

> MSF warns that Sanofi leaving antivenom market will lead to treatment crisis. Report

> Cipla gets first U.S. manufacturing plant with InvaGen buy. Article

> U.K. generics maker starts plant in Alabama. Story

Pharma Asia News

> Japan's PAFSC gives nods to Takeda's glatiramer, MSD's omarigliptin. News

> Samsung Bioepis wins South Korea nod for SB4, etanercept biosimilar. Story

> India denies Pfizer application for additional Xeljanz patents. More

> Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. Item

> Hutchison MediPharma's fruquintinib notches a second with proof-of-concept result. Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.